Amicus Therapeutics Appoints Margaret G. McGlynn, R.Ph., to Board of Directors

CRANBURY, N.J., Nov. 3 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq:
FOLD) today announced the appointment of Margaret G. McGlynn, R.Ph., to its
Board of Directors. Ms. McGlynn most recently served as President of Vaccines
and Infectious Diseases for Merck & Co., Inc.

John F. Crowley, President and CEO of Amicus Therapeutics stated, "Margie's
vast industry expertise and insight will be invaluable to Amicus as we execute
on our key strategic priorities and continue our focus on building shareholder
value with our innovative technologies. We are very pleased to welcome her to
our Board."

About Margaret G. McGlynn, R.Ph.
Margaret McGlynn recently retired from Merck & Co., Inc. after more than 26
years of service. Her most recent role was President of Merck Vaccines and
Infectious Diseases from 2005 through November 2009. McGlynn joined Merck in
1983 and served in a variety of marketing, sales and managed care roles. In
addition to her position at Merck, McGlynn serves as a member of the Board of
Directors for Air Products and Chemicals. She is also a member of the
National Industrial Advisory Committee at the University at Buffalo School of
Pharmacy and Pharmaceutical Sciences and recently served as a member of the
Global Alliance for Vaccine Immunization (GAVI) Board and Executive Committee.
McGlynn holds a B.S. in Pharmacy and a MBA in Marketing from the State
University of New York at Buffalo.

About Amicus Therapeutics
Amicus Therapeutics is a late-stage biopharmaceutical company developing
novel, oral therapeutics known as pharmacological chaperones for the treatment
of a range of human genetic diseases. Amicus is initially targeting lysosomal
storage disorders and diseases of neurodegeneration with unmet medical needs.

FOLD -G

SOURCE Amicus Therapeutics

Jenene Thomas, Director, Investor Relations, +1-609-662-5084, for Amicus
Therapeutics